FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD

Fakultatea

Foto de FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD

Foto de Institute of Oncology Ljubljana

Institute of Oncology Ljubljana

Liubliana, Eslovenia

Institute of Oncology Ljubljana-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2020

Trastuzumab emtansine plus non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer (Thelma): A single-arm, multicenter, phase Ib trial
Cancers, Vol. 12, Núm. 12, pp. 1-14

2018

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: Final results of the IBCSG 42-12/BIG 2-12 SNAP trial
Annals of Oncology, Vol. 29, Núm. 3, pp. 661-668

2016

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

2002

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial
Journal of the National Cancer Institute, Vol. 94, Núm. 14, pp. 1054-1065